Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
For people with type-2 diabetes, GLP-1 medications may begin lowering blood sugar within days or weeks after starting treatment
PRINCIPAL DISPLAY PANEL - 10 mg Capsule Bottle Label NDC 59417-101-10 Vyvanse (lisdexamfetamine dimesylate) capsules 10 mg CII Rx only 100 CAPSULES Takeda PRINCIPAL DISPLAY PANEL - 20 mg Capsule Bottle Label NDC 59417-102-10 Vyvanse (lisdexamfetamine dimesylate) capsules 20 mg CII Rx only 100 CAPSULES Takeda PRINCIPAL DISPLAY PANEL - 30 mg Capsule Bottle Label NDC 59417-103-10 Vyvanse (lisdexamfetamine dimesylate) capsules 30 mg CII Rx only 100 CAPSULES Takeda PRINCIPAL DISPLAY PANEL - 40 mg Capsule Bottle Label NDC 59417-104-10 Vyvanse (lisdexamfetamine dimesylate) capsules 40 mg CII Rx only 100 CAPSULES Takeda PRINCIPAL DISPLAY PANEL - 50 mg Capsule Bottle Label NDC 59417-105-10 Vyvanse (lisdexamfetamine dimesylate) capsules 50 mg CII Rx only 100 CAPSULES Takeda PRINCIPAL DISPLAY PANEL - 60 mg Capsule Bottle Label NDC 59417-106-10 Vyvanse (lisdexamfetamine dimesylate) capsules 60 mg CII Rx only 100 CAPSULES Takeda PRINCIPAL DISPLAY PANEL - 70 mg Capsule Bottle Label NDC 59417-107-10 Vyvanse (lisdexamfetamine dimesylate) capsules 70 mg CII Rx only 100 CAPSULES Takeda PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label NDC 59417-115-01 Vyvanse (lisdexamfetamine dimesylate) chewable tablets 10 mg 100 CHEWABLE TABLETS Chew tablets completely before swallowing
Are there any other serious side effects or risks I should know about
Injecting any substance into the body carries inherent risks, including the potential for allergic reactions, infections, and other adverse effects
Increased metabolism burns fat faster
[15] [13] Other notable adverse effects include: Hypoglycemia : Low risk when used as monotherapy, but increased when combined with insulin or sulfonylureas Injection site reactions : Erythema, pruritus, or discomfort in approximately 2% to 4% of patients Fatigue and dizziness : Reported in 5% to 8% of participants Increased heart rate : Mean increases of 2 to 4 beats per minute observed [1] [2] Serious adverse events were uncommon but included acute pancreatitis (approximately 0.2% incidence), gallbladder disease including cholecystitis and cholelithiasis (0.6% in diabetes trials and up to 2.5% in weight management trials, associated with rapid weight loss), and acute kidney injury, typically in the context of severe dehydration from gastrointestinal symptoms
US$ 25.57
US$ 26.23
US$ 20.29
US$ 24.80
US$ 24.30
US$ 27.83
